Free Trial

Wave Life Sciences Q1 2024 Earnings Report

Wave Life Sciences logo
$9.39 -0.01 (-0.11%)
As of 03/10/2025 04:00 PM Eastern

Wave Life Sciences EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.06
One Year Ago EPS
-$0.27

Wave Life Sciences Revenue Results

Actual Revenue
$12.54 million
Expected Revenue
$25.67 million
Beat/Miss
Missed by -$13.13 million
YoY Revenue Growth
N/A

Wave Life Sciences Announcement Details

Quarter
Q1 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Wave Life Sciences Earnings Headlines

Research Analysts Set Expectations for WVE FY2025 Earnings
The real reason gold is soaring (and likely to continue)
Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!
What is HC Wainwright's Forecast for WVE Q1 Earnings?
Q1 EPS Estimates for Wave Life Sciences Lowered by B. Riley
See More Wave Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Wave Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Wave Life Sciences and other key companies, straight to your email.

About Wave Life Sciences

Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

View Wave Life Sciences Profile

More Earnings Resources from MarketBeat